menu
    • menu

    Company profile for Genascence

    NEW Drugs in Dev: 2
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We’re taking on one of the largest problems in all of medicine — the leading cause of disability and chronic pain, and a significant risk factor for opioid addiction — osteoarthritis.We believe that gene therapy has the potential to go beyond treating rare, monogenic diseases, and tackle the major diseases affecting people around the world

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    GenascenceUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    3225 Ash St Palo Alto, CA, 94306-2240
    Telephone
    Telephone
    (707) 530-2523
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.genascence.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/genascence-corporation/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Grant Genascence Advanced Designation for Knee Osteoarthritis
    FDA Grant Genascence Advanced Designation for Knee Osteoarthritis

    16 Jul 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250716308556/en/Genascence-Announces-U.S.-Food-and-Drug-Administration-Grants-Regenerative-Medicine-Advanced-Therapy-Designation-to-GNSC-001-for-Knee-Osteoarthritis-OA

    BUSINESSWIRE
    16 Jul 2025
    Share Share
    Genascence Gene Therapy for Knee OA Meets Endpoint
    Genascence Gene Therapy for Knee OA Meets Endpoint

    12 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250512828808/en/Genascence-Phase-1b-DONATELLO-Trial-Evaluating-Potential-First-in-Class-Gene-Therapy-for-Knee-Osteoarthritis-OA-Meets-Primary-Endpoint-Showing-GNSC-001-Was-Safe-and-Well-Tolerated-Across-Multiple-Dosing-Arms

    BUSINESSWIRE
    12 May 2025
    Share Share
    Genascence Granted FDA Fast Track for GNSC-001 in Osteoarthritis
    Genascence Granted FDA Fast Track for GNSC-001 in Osteoarthritis

    12 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/genascence-granted-fda-fast-track-designation-for-gnsc-001-in-patients-with-osteoarthritis-oa-of-the-knee-302298409.html

    PR NEWSWIRE
    12 Nov 2024
    Share Share
    Genascence Announces Initiation of Phase 1b Clinical Trial of GNSC-001
    Genascence Announces Initiation of Phase 1b Clinical Trial of GNSC-001

    03 Jan 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/genascence-announces-initiation-of-phase-1b-clinical-trial-of-gnsc-001-gene-therapy-for-knee-osteoarthritis-oa-302022071.html

    PR NEWSWIRE
    03 Jan 2024
    Share Share
    Genascence to Present Full Data from Phase 1 Clinical Trial on GNSC-001
    Genascence to Present Full Data from Phase 1 Clinical Trial on GNSC-001

    24 Oct 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/genascence-to-present-full-data-from-phase-1-clinical-trial-on-gnsc-001-companys-lead-program-in-osteoarthritis-at-european-society-of-gene--cell-therapy-30th-annual-congress-301963549.html

    PR NEWSWIRE
    24 Oct 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search